184 related articles for article (PubMed ID: 38136292)
1. The Impact of Outpatient versus Inpatient Administration of CAR-T Therapies on Clinical, Economic, and Humanistic Outcomes in Patients with Hematological Cancer: A Systematic Literature Review.
Hansen DK; Liu YH; Ranjan S; Bhandari H; Potluri R; McFarland L; De Braganca KC; Huo S
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136292
[TBL] [Abstract][Full Text] [Related]
2. Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma.
Lyman GH; Nguyen A; Snyder S; Gitlin M; Chung KC
JAMA Netw Open; 2020 Apr; 3(4):e202072. PubMed ID: 32250433
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Healthcare Resource Utilization and Hospitalization Costs in Patients With Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy With Tisagenlecleucel: Results From the ELARA Study.
Fowler NH; Dickinson M; Ghosh M; Chen AI; Andreadis C; Tiwari R; Masood A; Ramos R; Jousseaume E; Thieblemont C; Dreyling M; Schuster SJ
Transplant Cell Ther; 2023 Jan; 29(1):60.e1-60.e4. PubMed ID: 36182104
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology and Predictors of 30-Day Readmission in CAR-T Cell Therapy Recipients.
Sharma A; Singh V; Deol A
Transplant Cell Ther; 2023 Feb; 29(2):108.e1-108.e7. PubMed ID: 36371048
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor T-cell treatment patterns in relapsed or refractory large B-cell lymphoma.
Seyedin R; Snider JT; Rajagopalan K; Wade SW; Gergis U
Future Oncol; 2023 Jul; 19(22):1535-1547. PubMed ID: 37578377
[TBL] [Abstract][Full Text] [Related]
6. Health Care Resource Utilization and Total Costs of Care Among Patients with Diffuse Large B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy in the United States.
Keating SJ; Gu T; Jun MP; McBride A
Transplant Cell Ther; 2022 Jul; 28(7):404.e1-404.e6. PubMed ID: 35354101
[TBL] [Abstract][Full Text] [Related]
7. Patient Perceptions of CAR-T Therapy in the USA: Findings from In-Depth Interviews.
Bixby TJ; Brittle CJ; Mangan PA; Stadtmauer EA; Kallenbach LR
Oncol Ther; 2023 Sep; 11(3):303-312. PubMed ID: 37210682
[TBL] [Abstract][Full Text] [Related]
8. Outpatient CAR T-Cell Therapy as Standard of Care: Current Perspectives and Considerations.
Gatwood K; Mahmoudjafari Z; Baer B; Pak S; Lee B; Kim H; Abernathy K; Dholaria B; Oluwole O
Clin Hematol Int; 2024; 6(2):11-20. PubMed ID: 38817307
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.
Cummings Joyner AK; Snider JT; Wade SW; Wang ST; Buessing MG; Johnson S; Gergis U
Adv Ther; 2022 Aug; 39(8):3560-3577. PubMed ID: 35689726
[TBL] [Abstract][Full Text] [Related]
10. Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia.
Myers GD; Verneris MR; Goy A; Maziarz RT
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33846220
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in hematologic malignancies: a living systematic review on comparative studies.
Saiz LC; Leache L; Gutiérrez-Valencia M; Erviti J; Rojas Reyes MX
Ther Adv Hematol; 2023; 14():20406207231168211. PubMed ID: 37138698
[TBL] [Abstract][Full Text] [Related]
12. Costs, effectiveness, and safety associated with Chimeric Antigen Receptor (CAR) T-cell therapy: Results from a comprehensive cancer center.
Chacim S; Monjardino T; Cunha JL; Medeiros P; Redondo P; Bento MJ; Mariz JM
PLoS One; 2022; 17(12):e0278950. PubMed ID: 36490296
[TBL] [Abstract][Full Text] [Related]
13. Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient Administration.
Alexander M; Culos K; Roddy J; Shaw JR; Bachmeier C; Shigle TL; Mahmoudjafari Z
Transplant Cell Ther; 2021 Jul; 27(7):558-570. PubMed ID: 33910041
[TBL] [Abstract][Full Text] [Related]
14. Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future.
Heine R; Thielen FW; Koopmanschap M; Kersten MJ; Einsele H; Jaeger U; Sonneveld P; Sierra J; Smand C; Uyl-de Groot CA
Hemasphere; 2021 Feb; 5(2):e524. PubMed ID: 33880433
[TBL] [Abstract][Full Text] [Related]
15. Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma.
Jagannath S; Joseph N; Crivera C; Kharat A; Jackson CC; Valluri S; Cost P; Phelps H; Slowik R; Klein T; Smolen L; Yu X; Cohen AD
Oncol Ther; 2023 Jun; 11(2):263-275. PubMed ID: 37014590
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
17. Identification of a Patient Suitable for CAR-T Cell Therapy in the Outpatient Setting: A Vodcast and Case Example.
Foley R; Kuruvilla J
Oncol Ther; 2024 Jun; 12(2):239-245. PubMed ID: 38662113
[TBL] [Abstract][Full Text] [Related]
18. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
[TBL] [Abstract][Full Text] [Related]
19. Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial.
McGarvey N; Ung B; Carattini T; Imanak K; Lee A; Campbell TB; Patwardhan P
Adv Ther; 2023 Oct; 40(10):4626-4638. PubMed ID: 37597153
[TBL] [Abstract][Full Text] [Related]
20. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.
Banerjee R; Marsal J; Huang CY; Lo M; Kambhampati S; Kennedy VE; Arora S; Wolf JL; Martin TG; Wong SW; Shah N
Transplant Cell Ther; 2021 Jun; 27(6):477.e1-477.e7. PubMed ID: 33831353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
